Late-Listed Patents Need "Careful Scrutiny" By FDA, Hatch And Waxman Say
This article was originally published in The Tan Sheet
Executive Summary
FDA should closely examine patents submitted for listing in the "Orange Book" in advance of generic competition, Sens. Edward Kennedy (D-Mass.) and Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) state in a letter to HHS Secretary Tommy Thompson.